Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Glycerol-3-phosphate dehydrogenase 2 (GPD2) is a mitochondrial enzyme that catalyzes the oxidation of glycerol-3-phosphate to dihydroxyacetone phosphate, transferring electrons from FAD to ubiquinone in the electron transport chain. This reaction forms a critical part of the glycerol phosphate shuttle, connecting glycolysis and oxidative phosphorylation, regulating NAD+/NADH balance, and contributing to lipid biosynthesis. GPD2 is structurally conserved and shares homology with bacterial GlpD, which has been extensively characterized. GPD2 plays essential roles in cellular metabolism, is regulated under various stress conditions, and alterations in its activity are associated with cancer, obesity, and diabetes. It is a candidate metabolic target but not the subject of approved direct drugs at present.
Inhibitors would block electron transfer from glycerol-3-phosphate, impairing NADH/FADH2 reoxidation and mitochondrial function. Targeting GPD2 could disrupt the glycerol phosphate shuttle, affecting glycolysis and lipid biosynthesis.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Glycerol-3-phosphate dehydrogenase 2 (GPD2).